Skip to main content
    T

    Travere Therapeutics Inc (TVTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $49.70
    -0.95 (-1.88%)

    Market Cap: $4.86B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Travere Therapeutics Inc (TVTX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Travere Therapeutics are Viridian Therapeutics (VRDN), Trevi Therapeutics (TRVI) and Vera Therapeutics (VERA). By market cap, Travere Therapeutics ranks 6th of the 13 companies on this page; TG Therapeutics (TGTX) is the largest at $9.75B. The median P/E of the 3 companies with a P/E is 87.2x.

    Peer Comparison

    TVTX's ROIC of -23.1% is above the peer median of -31.0%, and its revenue growth of 36.2% is below the median of 42.4%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Travere Therapeutics (TVTX)$4.86BN/A7.2x-18.7%-23.1%36.2%0.00%
    Viridian Therapeutics Inc (VRDN)$3.51BN/A128.5x0.0%-41.8%-63.5%0.00%
    Trevi Therapeutics Inc (TRVI)$1.95BN/AN/A0.0%N/A0.0%0.00%
    Vera Therapeutics Inc (VERA)$2.03BN/A189.3x0.0%-83.0%0.0%0.00%
    Viking Therapeutics Inc (VKTX)$3.73BN/AN/A0.0%-61.0%0.0%0.00%
    PTC Therapeutics Inc (PTCT)$5.30BN/A5.2x-9.2%18.1%69.6%0.00%
    TG Therapeutics Inc (TGTX)$9.75B87.2x11.1x11.8%11.0%60.7%0.00%
    Crispr Therapeutics AG (CRSP)$4.10BN/A155.2x0.0%-20.3%1325.0%0.00%
    Protagonist Therapeutics Inc (PTGX)$8.55B27.7x15.8x62.0%N/A5724.0%0.00%
    Dianthus Therapeutics Inc. (DNTH)$5.17BN/AN/A0.0%N/A205.6%0.00%
    Pharvaris BV (PHVS)$2.36BN/AN/A0.0%N/A0.0%0.00%
    Arcutis Biotherapeutics Inc (ARQT)$3.57B129.3x7.0x5.9%7.8%45.1%0.00%
    Mirum Pharmaceuticals Inc (MIRM)$6.14BN/A8.9x-134.7%-133.6%39.6%0.00%
    Peer median$3.91B87.2x13.4x0.0%-31.0%42.4%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Travere Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Viridian Therapeutics Inc (VRDN)
    Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses.
    VRDN competitors
    Trevi Therapeutics Inc (TRVI)
    Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious...
    TRVI competitors
    Vera Therapeutics Inc (VERA)
    Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases...
    VERA competitors
    Viking Therapeutics Inc (VKTX)
    Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders.
    VKTX competitors
    PTC Therapeutics Inc (PTCT)
    PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders.
    PTCT competitors
    TG Therapeutics Inc (TGTX)
    TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development...
    TGTX competitors
    Crispr Therapeutics AG (CRSP)
    CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases.
    CRSP competitors
    Protagonist Therapeutics Inc (PTGX)
    Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical...
    PTGX competitors
    Dianthus Therapeutics Inc. (DNTH)
    Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops...
    DNTH competitors
    Pharvaris BV (PHVS)
    Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies.
    PHVS competitors
    Arcutis Biotherapeutics Inc (ARQT)
    Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
    ARQT competitors
    Mirum Pharmaceuticals Inc (MIRM)
    Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies...
    MIRM competitors

    Frequently Asked Questions About TVTX

    Who are Travere Therapeutics' main competitors?

    The companies most similar to Travere Therapeutics include Viridian Therapeutics (VRDN), Trevi Therapeutics (TRVI), Vera Therapeutics (VERA), Viking Therapeutics (VKTX) and PTC Therapeutics (PTCT), listed from the closest match.

    Who is Travere Therapeutics' biggest competitor?

    TG Therapeutics (TGTX) is the largest of the similar companies at $9.75B; Viridian Therapeutics (VRDN) is the closest match by business profile, size, sector and industry.

    How does TVTX stock compare with its competitors?

    TVTX's P/S is 7.2x against a peer median of 13.4x; its net margin is -18.7% against a peer median of 0.0%.

    Which of Travere Therapeutics' competitors pays a higher dividend?

    Travere Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Travere Therapeutics bigger than its competitors?

    No. Travere Therapeutics is 6th by market cap among the 13 companies on this page; the largest is TG Therapeutics (TGTX) at $9.75B.